David J Hiller1, Carol Meschonat, Roger Kim, Benjamin D L Li, Quyen D Chu. 1. Department of Surgery and Division of Surgical Oncology, Louisiana State University Health Sciences Center in Shreveport and the Feist-Weiller Cancer Center, Shreveport, LA, USA.
Abstract
BACKGROUND: Chemokine receptor CXCR4 is a marker of metastatic disease. We found initially that CXCR4 level is a predictive marker for patients with locally advanced breast cancer (LABC). We now confirm our initial observations. METHODS: We evaluated 77 LABC patients who had neoadjuvant therapy. Specimens were taken at the time of definitive operation. CXCR4 levels were detected with Western blots. CXCR4 expression >6.6-fold over known concentration of HeLa cells was defined as high. Primary endpoints were cancer recurrence and death. Statistical analyses were Kaplan-Meier curves, log-rank test, and Cox proportional hazard model. RESULTS: Median follow-up time was 42 months; 55 patients (71%) had low CXCR4 level. The 5-year overall survival for the low and high CXCR4 group was 78% and 50%, respectively (P = .015). The 5-year disease-free survival (DFS) for the low and high CXCR4 group was 67% and 41%, respectively (P = .024). On multivariate analysis, CXCR4 overexpression (P = .003) and nodal status (P = .044) were independent predictors of overall survival; CXCR4 overexpression (P = .003) and nodal status (P = .026) were also independent predictors of DFS. CONCLUSION: We confirmed that high CXCR4 levels in cancer specimens after neoadjuvant therapy independently predict a poor outcome for patients with LABC.
BACKGROUND: Chemokine receptor CXCR4 is a marker of metastatic disease. We found initially that CXCR4 level is a predictive marker for patients with locally advanced breast cancer (LABC). We now confirm our initial observations. METHODS: We evaluated 77 LABC patients who had neoadjuvant therapy. Specimens were taken at the time of definitive operation. CXCR4 levels were detected with Western blots. CXCR4 expression >6.6-fold over known concentration of HeLa cells was defined as high. Primary endpoints were cancer recurrence and death. Statistical analyses were Kaplan-Meier curves, log-rank test, and Cox proportional hazard model. RESULTS: Median follow-up time was 42 months; 55 patients (71%) had low CXCR4 level. The 5-year overall survival for the low and high CXCR4 group was 78% and 50%, respectively (P = .015). The 5-year disease-free survival (DFS) for the low and high CXCR4 group was 67% and 41%, respectively (P = .024). On multivariate analysis, CXCR4 overexpression (P = .003) and nodal status (P = .044) were independent predictors of overall survival; CXCR4 overexpression (P = .003) and nodal status (P = .026) were also independent predictors of DFS. CONCLUSION: We confirmed that high CXCR4 levels in cancer specimens after neoadjuvant therapy independently predict a poor outcome for patients with LABC.
Authors: Hans Jürgen Wester; Ulrich Keller; Margret Schottelius; Ambros Beer; Kathrin Philipp-Abbrederis; Frauke Hoffmann; Jakub Šimeček; Carlos Gerngross; Michael Lassmann; Ken Herrmann; Natalia Pellegata; Martina Rudelius; Horst Kessler; Markus Schwaiger Journal: Theranostics Date: 2015-03-01 Impact factor: 11.556
Authors: G K Chimal-Ramírez; N A Espinoza-Sánchez; D Utrera-Barillas; L Benítez-Bribiesca; J R Velázquez; L A Arriaga-Pizano; A Monroy-García; E Reyes-Maldonado; M L Domínguez-López; Patricia Piña-Sánchez; E M Fuentes-Pananá Journal: Biomed Res Int Date: 2013-05-09 Impact factor: 3.411